BiotechTube

ALN-CC5 + Sterile Normal Saline (0.9% NaCl)

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial Timeline

Jan 1, 2015 → Aug 1, 2017

NCT ID
NCT02352493

About ALN-CC5 + Sterile Normal Saline (0.9% NaCl)

ALN-CC5 + Sterile Normal Saline (0.9% NaCl) is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT02352493. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02352493Phase 1/2Completed

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
LNP023NovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51

Other Products from Alnylam Pharmaceuticals

PatisiranPhase 3
74
PatisiranPhase 3
74
Givosiran + PlaceboPhase 3
74
Nucresiran + Sterile Normal Saline (0.9% NaCl)Phase 3
74
LumasiranPhase 3
74